Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals …
Sep 10, 2024 · Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations
ANI Pharmaceuticals to Further Expand Rare Disease Business …
Jun 24, 2024 · PRINCETON, N.J. and ATLANTA, June 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) and Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) today...
HOME - Alimera Sciences Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer.
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Jun 25, 2024 · Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
PRESS RELEASES - Alimera Sciences
Find the latest news and updates from Alimera Sciences, a global pharmaceutical company focused on retinal health and vision. Read about its financial results, merger with ANI Pharmaceuticals, clinical trials and scientific data.
Alimera Improves Capital Structure, Strengthens Balance
ATLANTA, March 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and...
ANI Pharmaceuticals completes acquisition of Alimera Sciences
Sep 17, 2024 · ANI Pharmaceuticals completed the acquisition of Alimera Sciences, a company with two ophthalmology products, Iluvien and Yutiq, and a rare disease platform. The transaction expands ANI's global footprint, revenue, and accretion potential in rare diseases.
Alimera Sciences shares jump by 77% after being acquired by ANI
Jun 24, 2024 · ANI Pharmaceuticals will buy Alimera Sciences, a rare disease company with two ophthalmology products, Iluvien and Yutiq, for $5.50 per share. The deal is expected to close in Q3 2024 and add $105m in revenues for ANI.
Alimera Files Lawsuit Against ANI To Enforce Merger Deal, Stock …
Sep 10, 2024 · (RTTNews) - Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of Chancery against ANI Pharmaceuticals, Inc. (ANIP)...
Alimera Sciences To Be Acquired By ANI Pharma For $381 Mln; …
Jun 24, 2024 · (RTTNews) - Monday, Alimera Sciences, Inc. (ALIM) announced an agreement to be acquired by ANI Pharmaceuticals, Inc. (ANIP) for approximately $381 million. ALIM stock is currently up 77% on the...
- Some results have been removed